期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

低钙透析对低甲状旁腺激素血症血液透析患者骨盐代谢的影响 被引量：8

原文传递
导出
摘要 近年无力型肾性骨病在终末期肾病（ESRD）中的比例显著升高，并严重影响患者生活质量和预后。低甲状旁腺激素（PTH）血症既是无力型骨病的重要特征，也是其发生的重要因素。
作者 邹建洲 刘中华 沈波 滕杰 陈利明 方艺 薛宁 丁小强
机构地区 复旦大学附属中山医院肾内科
出处 《中华肾脏病杂志》 CAS CSCD 北大核心 2010年第7期562-563,共2页 Chinese Journal of Nephrology
基金 上海市科委重大项目（08dz1900602）
关键词 血液透析患者 甲状旁腺激素 低钙透析 血症 代谢 骨盐 肾性骨病 终末期肾病
分类号 R692.5 [医药卫生—泌尿科学]
  • 相关文献

参考文献8

  • 1Moe S, Drueke T, Cunningham J, et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outeomes(KDIGO). Kidney Int, 2006, 69: 1945-1953.
  • 2Gal-Moscovici A, Popovtzer MM. New worldwide trends in presentation of renal osteodystrophy and its relationship to parathyroid hormone levels. Clin Nephrol, 2005, 63: 284- 289.
  • 3Salusky I, Goodman WG. Adynamic renal osteodystrophy: is there a problem? J Am Soc Nephrol, 2001, 12: 1978-1985.
  • 4李峻岭,郑法雷.无力型肾性骨病发病增多:一个应当引起重视的问题[J].中国血液净化,2002,1(2):6-10. 被引量：3
  • 5Coen G, Ballanti P, Bonucci E, et al. Bone markers in the diagnosis of low turnover osteodystrophy in hemodialysis patients. Nephrol Dial Transplant, 1998, 13: 2294-2302.
  • 6Salusky IB, Ramirez JA, Oppenheim WL, et al. Biochemical markers of renal osteodystrophy in pediatric patients undergoing CAPD/CCPD. Kidney Int, 1994, 45: 253-258.
  • 7Fukagawa M, Akizawa T, Kurokawa K. Is aplastic osteodystrophy a disease of malnutrition? Curr Opin Nephrol Hypertens, 2000, 9: 363-367.
  • 8Avram MM, Sreedhara R, Oo Kk, et ah Prognostic value of enrollment nutritional markers including novel predictors PTH and prealbumin in hemodialysis patients: 12 years of follow-up. J Am Soc Nephrol, 1999, 10: 272A.

二级参考文献22

  • 1[1]Llach F, Bover J. Renal osteodystrophies. In Brenner B(ed). Brenner & Rector' s The Kidney, 6th ed. Beijing, Science Press, Harcourt Asia W. B. Saunders, 2001, 2121 - 2125
  • 2[2]Salusky IB, Goodman WG.Adynamic renal osteodystrophy: Is there a problem? J Am Soc Nephrol, 2001,12:1978 - 1985
  • 3[3]Schrooten I, Elseviers MM, Lamberts LV, et al. Increased serum strontium levels in dialysis patients. Kidney Int, 2000, 57:1107 -1114
  • 4[4]Couttenye MM, Haese PC, Verschoren WJ, et al. Low bone turnover in patient with renal failure. Kidney Int, 1999, 56 (Suppl73) :S70 - S76
  • 5[5]Roe S, Cassidy MJ.Diagnosis and monitoring of renal osteodystrophy. Curr Opin Nephrol Hypertens, 2000, 9: 675 - 681
  • 6[6]Mucsi I, Hercz G.Relative hypoparathyroidism and adynamic bone disease. Am J Med Sci, 1999, 317:405 - 409
  • 7[7]Torres A, Lorenzo V, Hernandez D, et al. Bone disease in predialysis, hemodialysis, and CAPD patients: Evidence of a better bone response to PTH. Kidney Int, 1995,47:1434 - 1442
  • 8[8]Nagaba Y, Heishi M, Tsukanoto Y, et al. Vitamin D receptor gene polymorphisms affect secondery hyperparathyroidism in hemodialyzed patients. Am J Kidney Dis, 1998, 32: 464 - 469
  • 9[9]Hernandez A, Concepcion MT, Rodriguez M, et al. High phosphrus diet increases preproPTH Mrna independent of calcium and calcitriol in normal rats. Kidney Int, 1996, 50:1872- 1878
  • 10[10]Gonzalez E, Martin K.Coordinate regulation of PTH/PTHrP receptors by PTH and calcitriol in UMR 106 - 01 osteoblast - like cells. Kidney Int, 1996, 50:63 - 70

共引文献2

同被引文献89

  • 1郭云珊,袁伟杰,张国兆.甲状旁腺激素的不同检测方法及其在肾性骨病诊断中的价值[J].中华肾脏病杂志,2006,22(3):187-190. 被引量：12
  • 2慢性肾脏病骨代谢及其疾病的临床实践指南——指南3:血清磷水平的评价[J].中国血液净化,2006,5(2):98-98. 被引量：2
  • 3Raggi P, Vukicevic S, Moys6s RM, et al. Ten-year experience with sevelamer and calcium salts as phosphate binders. Clin J Am Soc Nephrol, 2010, 5 Suppl 1: S31- S40.
  • 4Sturtevant JM, Hawley CM, Reiger K, et al. Efficacy and side-effect profile of sevelamer hydrochloride used in combination with conventional phosphate binders. Nephrology (Carlton), 2004, 9: 406-413.
  • 5Nikolov IG, Joki N, Maizel J, et al. Pleiotropic effects of the non-calcium phosphate binder sevelamer. Kidney Int Suppl, 2006, 105: S16-S23.
  • 6Noordzij M, Korevaar JC, Boeschoten EW, et al. Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD) Study Group. The Kidney Disease Outcomes Quality Initiative (K/DOQI) Guideline for Bone Metabolism and Disease in CKD: association with mortality in dialysis patients. Am J Kidney Dis, 2005, 46: 925-932.
  • 7Slatopolsky EA, Burke SK, Dillon MA. RenaGel, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers scram phosphorus and parathyroid hormone. The RenaGel Study Group. Kidney Int, 1999, 55: 299-307.
  • 8Goldberg DI, Dillon MA, Slatopolsky EA, et al. Effect of RenaGel, a non-absorbed, calcium-and aluminium-free phosphate binder, on serum phosphorus, calcium, and intact parathyroid hormone in end-stage renal disease patients. Nephrol Dial Transplant, 1998, 13: 2303-2310.
  • 9Cassidy M J, Owen JP, Ellis HA, et al. Renal osteodystrophy and metastatic calcification in long-term continuous ambulatory peritoneal dialysis. Q J Med, 1985, 54: 29-48.
  • 10Slatopolsky EA, Burke SK, Dillon MA. RenaGel, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. The RenaGel Study Group. Kidney Int, 1999, 55: 299-307.

引证文献8

二级引证文献82

中华肾脏病杂志
2010年 第7期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部